Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

29.96 -0.68 (-2.22%)
Streaming Delayed Price Updated: 11:08 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
7 Analysts Have This To Say About Celldex Therapeutics ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On Celldex Therapeutics ↗
 
Via Benzinga
News headline image
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.